Author:
Bianco Assunta,Nicoletti Tommaso,Traini Emanuela,Del Giacomo Paola,Del Gatto Valeria,Lucchini Matteo,Rota Carlo A.,Mirabella Massimiliano
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism
Reference6 articles.
1. Scappaticcio L, Castellana M, Virili C, Bellastella G, Centanni M, Cannavò S, Campennì A, Ruggeri RM, Giovanella L, Trimboli P (2019) Alemtuzumab-induced thyroid events in multiple sclerosis: a systematic review and meta-analysis. J Endocrinol Invest 43:219–229
2. Devonshire V, Phillips R, Wass H, Da Roza G, Senior P (2018) Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations. J Neurol 265:2494–2505
3. Tuohy O, Costelloe L, Hill-Cawthorne G, Bjornson I, Harding K, Robertson N et al (2015) Alemtuzumab treatment of multiple sclerosis: long term safety and efficacy. J Neurol Neurosurg Psychiatry 86:208–215
4. Pariani N, Willis M, Muller I, Healy S, Nasser T, McGowan A et al (2018) Alemtuzumab-induced thyroid dysfunction exhibits distinctive clinical and immunological features. J Clin Endocrinol Metab 103:3010–3018
5. Vos XG, Endert E, Zwinderman K, Tijssen JGP, Wiersinga WM (2016) Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves’ hyperthyroidism. J Clin Endocrinol Metab 26:765–769
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献